Azitra, Inc. to Present at the H.C. Wainwright 27th Annual Global Investment Conference
AZTR(AZTR) BRANFORD, Conn., Sept. 4, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that Cofounder and Chief Operating Officer, Travis Whitfill PhD MPH, will...
Azitra, Inc. Announces First Patient Dosed in Phase 1/2 Trial for ATR-04 Program Targeting Oncology Patients with EGFRi-Associated Rash
AZTRBRANFORD, Conn., Aug. 27, 2025 /PRNewswire/ -- Azitra, Inc. ("Azitra") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the dosing of the first patient in its Phase 1/2 clinical trial of...
Azitra, Inc. Announces Q2 2025 Results and Provides Business Updates
AZTRBRANFORD, Conn., Aug. 11, 2025 /PRNewswire/ -- Azitra, Inc. ("Azitra") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the quarter ended June 30, 2025, and provided...
Azitra, Inc. Announces Reverse Stock Split
AZTRCommon Stock Will Begin Trading on a Split-Adjusted Basis on August 21, 2025 BRANFORD, Conn., Aug. 11, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced...
Azitra To Highlight Recent Updates And Progress In Its Pipeline, Including ATR-12, Currently In Phase 1b Clinical Trial In Adult Patients With Netherton Syndrome And ATR-04, At 2025 BIO International Convention
AZTRAzitra To Present Data Highlighting Phase 1/2 Clinical Trial Of ATR04-484 In EGFR Inhibitor-Associated Rash At 2025 ASCO Annual Meeting
AZTRAzitra To Present Phase 1/2 Study Of ATR04-484 For EGFR Inhibitor-Associated Rash
AZTRAnitra Q1 EPS $(0.23) Up From $(4.32) YoY
AZTRAzitra Enters $20M Share Purchase Agreement with Alumni Capital to Advance Clinical Program
AZTRWatching Azitra; Zacks Small-Cap Research Gives Stock $3 Price Valuation
AZTRAzitra FY24 EPS $(2.37) Vs $(54.98) YoY; Revenue $7.5K Vs $686K YoY
AZTRAzitra Prices 4,857,780 Share Public Offering Of Common Stock At $0.30/Share
AZTRAzitra Commences Public Offering Of Shares Of Its Common Stock Or Pre-funded Warrants In Lieu Thereof
AZTRAzitra Presents Preclinical Data From ATR-04 At Society Of Investigative Dermatology Annual Meeting
AZTR